查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球尿路癌市場評估：按類型、方式、最終用戶、地區、機會、預測（2017-2031）
市場調查報告書
商品編碼
1419609

全球尿路癌市場評估：按類型、方式、最終用戶、地區、機會、預測（2017-2031）

Urinary Tract Cancer Market Assessment, By Types, By Modality, By End-users, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 222 Pages | 商品交期: 3-5個工作天內

價格

預計2023年全球泌尿道癌症市場規模將達21.1億美元，2031年將達65.5億美元，2024-2031年預測期內複合年增長率為15.21%。 多種因素，包括泌尿道癌症盛行率上升、創新療法、診斷技術的進步、認識和篩檢工作的提高、老年人口的增長以及聯合療法的採用，正在推動全球泌尿道癌症的發展。市場。

隨著世界人口老化和生活方式因素的持續存在，被診斷出患有尿路癌的人數正在增加。 創新治療方法也正在推動市場擴張。 近年來，標靶治療、免疫療法和精準醫學方法的發展取得了顯著進展，提供了更有效、更侵入性的治療選擇。 這些突破對全球泌尿道癌症市場的成長做出了重大貢獻。 分子標記物和非侵入性診斷測試的發展使得早期檢測成為可能，從而能夠及時幹預並獲得更好的治療結果。

意識和篩檢工作，包括公共衛生運動和政府舉措，有助於泌尿道癌的早期診斷，這對於改善患者的治療效果至關重要。 人口老化也是一個重要的驅動因素，因為老年人罹患這些癌症的風險更高。 人口趨勢和不斷增長的醫療保健支出將進一步增加對治療的需求。 製藥和生物技術公司對研發的投資正在幫助發現新的治療選擇和組合。 因此，已開發和新興市場醫療保健基礎設施的擴大和准入的改善使患者更容易獲得診斷、治療和支持性護理，從而推動了全球泌尿道癌症市場的發展。

尿路癌盛行率增加

全球泌尿道癌症盛行率的增加是全球泌尿道癌症市場的主要成長動力。 在全球範圍內，考慮到病例的絕對數量，膀胱癌在最受歡迎的癌症中排名第十。 膀胱癌是男性第六常見癌症。 腎癌（也稱為腎癌或腎細胞癌）是全球第 14 位最常診斷的癌症。 它是男性第 9 位最常見癌症，女性第 14 位最常見癌症。 吸煙、接觸某些化學物質和不健康的飲食習慣等因素會增加這些癌症的盛行率。

病例數的增加導致對該領域的診斷工具、創新治療方法以及研究和開發的需求增加。 需求的激增為製藥公司、醫療器材製造商和醫療保健提供者創造了開發和提供改進的診斷、標靶治療和支持治療的機會，推動了全球泌尿道癌症市場的發展。 因此，隨著尿路癌負擔的增加，市場預計將擴大，以應對不斷變化的醫療需求。

擴大研發

知名公司正大力投資研發和創新，特別關注開發泌尿道癌的先進篩檢方法。 這些投資對全球泌尿道癌症市場產生重大影響。 透過實施分子標記和非侵入性診斷測試等尖端篩檢技術，這些公司正在為早期檢測和診斷做出貢獻，這是改善患者治療結果的關鍵因素。 積極主動的方法增加了早期介入的可能性，從而發展出更有效和高效的治療方法。 因此，它將加強泌尿道癌症市場的成長和前景，同時對患者的治療和預後產生積極影響。

例如，2023 年 3 月，伯明翰大學的研究人員與液體活檢癌症檢測和篩檢公司 Nonacus 合作，開發了一種非侵入性識別膀胱癌的創新測試。 這項開創性的測試在歐洲泌尿外科協會年度大會上以 GALEAS Bladder 的名稱正式推出。 這種利用尿液樣本的分子測試提供了一種快速、準確地檢測膀胱癌的方法，增強了診斷過程，同時最大限度地減少了侵入性膀胱鏡檢查的需要。

本報告針對全球泌尿道癌症市場進行研究和分析，提供市場規模和預測、市場動態、主要公司趨勢和展望等。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章全球泌尿道癌症市場展望（2017-2031）

  • 市場規模與預測
    • 金額
    • 數量
  • 依類型
    • 腎癌
    • 膀胱癌
    • 輸尿管癌、腎盂癌
    • 尿道癌
  • 按方式
    • 診斷
    • 治療
  • 按最終用戶
    • 醫院
    • 門診手術中心
    • 專科診所
    • 藥房
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 市佔率：依公司劃分（2023 年）

第 5 章全球泌尿道癌市場前景：按地區劃分（2017-2031 年）

  • 北美
    • 市場規模與預測
    • 依類型
    • 按方式
    • 按最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印尼
    • 菲律賓
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第 6 章市場地圖（2023 年）

  • 依類型
  • 按方式
  • 按最終用戶
  • 按地區

第 7 章宏觀環境與產業結構

  • 需求與供給分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 生長抑制因素（問題、限制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新技術

第 10 章公司主要情況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析（2023 年）
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家公司進入市場）
  • 專利分析（如果適用）

第 11 章價格分析

第 12 章案例研究

第 13 章主要公司展望

  • Bristol-Myers Squibb Company
  • Novartis AG
  • Merck & Co., Inc.
  • Exelixis, Inc.
  • AstraZeneca plc
  • Astellas Pharma Inc.
  • Johnson & Johnson Innovative Medicine
  • Bayer AG
  • Pfizer, Inc.
  • Seagen Inc.

第 14 章策略建議

第 15 章關於我們公司，免責聲明

Product Code: MX10924

Global urinary tract cancer market size was valued at USD 2.11 billion in 2023, which is expected to reach USD 6.55 billion in 2031, with a CAGR of 15.21% for the forecast period between 2024 and 2031. Various factors are propelling the global urinary tract cancer market, such as the rising prevalence of urinary tract cancer, innovative treatment methodologies, advancements in diagnostic methods, enhanced awareness and screening efforts, a growing geriatric population, and the adoption of combination therapies.

As the global population continues to age and lifestyle factors persist, the number of individuals being diagnosed with urinary tract cancer is increasing. Innovative treatment methodologies are another driving force behind the market's expansion. Over the past few years, there has been remarkable progress in developing targeted therapies, immunotherapies, and precision medicine approaches, which provide more effective and often less invasive treatment options. These breakthroughs have significantly helped in the growth of global urinary tract cancer market. The development of molecular markers and non-invasive diagnostic tests enables early detection, facilitating timely interventions and better treatment outcomes.

Increased awareness and screening efforts, including public health campaigns and government initiatives are contributing to the early diagnosis of urinary tract cancers, which is essential for improved patient outcomes. The aging demographic is another key driver, as the elderly population is at a higher risk for these cancers. The demographic trend and increasing healthcare expenditure further fuel the demand for treatments. Investment in research and development by pharmaceutical and biotechnology companies is instrumental in discovering novel therapeutic options and combination therapies. Consequently, expanding healthcare infrastructure and improved accessibility in both developed and emerging markets ensures patients have better access to diagnosis, treatment, and supportive care, thus propelling the global urinary tract cancer market forward.

Increasing Prevalence of Urinary Tract Cancer

The increasing global prevalence of urinary tract cancer is a significant driver propelling the growth of global urinary tract cancer market. On a global scale, bladder cancer ranks as the tenth most prevalent type of cancer when considering the absolute number of cases. Among men, bladder cancer stands as the sixth most common cancer. Kidney cancer, alternatively referred to as renal cancer or renal cell adenocarcinoma, holds the rank of being the 14th most frequently diagnosed cancer globally. Specifically, it stands as the ninth most common cancer among men and the 14th most common cancer among women. Factors such as smoking, exposure to certain chemicals, and unhealthy dietary habits contribute to the growing prevalence of these cancers.

The increasing number of cases has led to a growing demand for diagnostic tools, innovative treatment approaches, and research and development in the field. The surge in demand has created opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers to develop and offer improved diagnostic methods, targeted therapies, and supportive care, ultimately boosting the global urinary tract cancer market. Consequently, the market is poised for expansion to meet the evolving healthcare needs associated with the growing urinary tract cancer burden.

Expanding Research and Development Endeavors

Prominent companies are significantly investing in research and innovation, with a specific focus on developing advanced screening methods for urinary tract cancers. These investments have a profound impact on the global urinary tract cancer market. By introducing cutting-edge screening techniques, such as molecular markers and non-invasive diagnostic tests, these companies are contributing to early detection and diagnosis, a crucial factor in improving patient outcomes. The proactive approach enhances the prospects for early intervention and leads to the development of more effective and efficient treatments. In turn, it bolsters the growth and potential of the urinary tract cancer market while positively impacting patient care and prognosis.

For instance, in March 2023, the partnership between researchers at the University of Birmingham and the liquid biopsy cancer detection and screening company Nonacus yielded an innovative test for the non-invasive identification of bladder cancer. The breakthrough was officially unveiled at the Annual Meeting of the European Association of Urology under the name GALEAS Bladder. The molecular test, which utilizes urine samples, offers a rapid and precise means of detecting bladder cancer, enhancing the diagnostic process while minimizing the necessity for invasive cystoscopies.

Government Initiatives

Numerous governments across the world have initiated public awareness programs aimed at educating their populations about urinary tract-related disorders and the importance of early detection and prevention. These efforts play a pivotal role in supporting the growth of the global urinary tract cancer market. Through increasing awareness about the risk factors, symptoms, and the need for regular screenings, these programs contribute to the early diagnosis of kidney and urinary tract cancers. Consequently, early detection often leads to more effective treatment options, better patient outcomes, and an increased demand for diagnostic and therapeutic solutions, thereby bolstering the growth prospects of the global urinary tract cancer market. As an example, during September 2023, the American Kidney Fund (AKF) initiated educational awareness initiatives dedicated to two uncommon kidney ailments: complement 3 glomerulopathy (C3G) and IgA nephropathy (IgAN). These campaigns were sponsored by Novartis, designed to furnish patients with comprehensive knowledge about these conditions and link them with valuable resources, aiding in their comprehension and effective management of these rare kidney diseases.

Growing Demand for Kidney Cancer Treatment Options

Patients, medical practitioners, and healthcare institutions proactively pursue innovative and effective treatment modalities to address the mounting health issue. The global urinary tract cancer market is witnessing significant progress, marked by the advent of targeted therapies and immunotherapies, thereby expanding the therapeutic landscape, and elevating the prognosis for kidney cancer patients. The increase in demand highlights the critical necessity for comprehensive and individualized solutions in the fight against kidney cancer, as part of the broader urinary tract cancer market. As an example, in October 2023, Merck in the United States and Canada, disclosed that the Drug Controller General of India (DCGI) granted approval for Keytruda (pembrolizumab), MSD's anti-PD-1 therapy, to be used in treating renal cell carcinoma in adults.

Emerging Advanced Diagnostic Solutions

Increasing demand for cutting-edge diagnostic solutions is becoming evident in the global urinary tract cancer market. The surge is propelled by various factors, primarily the increasing global prevalence of urinary tract cancer. Both patients and healthcare professionals are progressively pursuing precise, efficient, and less invasive diagnostic approaches to detect these cancers at earlier stages, to enhance treatment outcomes. Advanced diagnostic techniques, including molecular markers and non-invasive tests, offer early detection and reduced reliance on invasive procedures. For instance, Genomictree, a firm specializing in biomarker-driven cancer diagnostics, announced in May 2023 that it launched its bladder cancer diagnostic product, EarlyTect-BCD, in the United States.

Future Market Scenario

The future of global urinary tract cancer market looks promising, with a landscape full of opportunities. The optimistic outlook results from various factors. The continuous progress in research and development which is driving the exploration of innovative treatment modalities, encompassing immunotherapies, precision medicine, and targeted therapies. These emerging therapeutic options offer patients with more effective and less invasive alternatives, ultimately enhancing their quality of life and long-term prognosis.

Also, the increasing incidence of urinary tract cancer, covering bladder and kidney cancers, spurs the demand for diagnostic and treatment solutions. With factors like the growing geriatric population and lifestyle-related risks contributing to its prevalence, the market is poised for expansion. Moreover, increased awareness about early detection and screening, alongside improved healthcare infrastructure and accessibility in developed and emerging markets contribute to the industry's growth. Collectively, these elements are showing a promising future for the global urinary tract cancer market, presenting abundant prospects for research, innovation, and enhanced patient care.

Key Players Landscape and Outlook

Key players are proactively forging sales agreements to optimize the distribution of their products in the global urinary tract cancer market. These agreements broaden the reach and efficiency of their diagnostics, therapies, and medical devices. Partnerships with established distributors or healthcare networks empower these organizations to guarantee effective delivery of their products to healthcare providers and patients, enhancing accessibility and quality of patient care. The approach holds particular significance in urinary tract cancer, where early detection and timely treatment are paramount. Collaborative sales agreements are playing a pivotal role in addressing diagnostic and treatment challenges, ultimately benefiting patients, contributing to the market's expansion.

In August 2023, a synthetic royalty agreement worth USD 500 million was established between Royalty Pharma plc and Ferring Pharmaceuticals, headquartered in Saint-Prex, Switzerland. The agreement involves specified sales of Ferring's novel gene therapy designed for bladder cancer. According to the terms, Royalty Pharma will make an upfront payment of USD 300 million to Ferring and potentially an additional USD 200 million in milestone payments. In return, Royalty Pharma will receive royalties on the sales of Ferring's intravesical gene therapy known as Adstiladrin (nadofaragene firadenovec-vncg).

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Urinary Tract Cancer Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Types
    • 4.2.1. Kidney Cancer
    • 4.2.2. Bladder Cancer
    • 4.2.3. Ureteric and Renal Pelvic Cancer
    • 4.2.4. Urethral Cancer
  • 4.3. By Modality
    • 4.3.1. Diagnosis
      • 4.3.1.1. Urinalysis
      • 4.3.1.2. Cytology
      • 4.3.1.3. Cystoscopy
      • 4.3.1.4. MRI Scan
      • 4.3.1.5. CT Scan
    • 4.3.2. Treatment
      • 4.3.2.1. Surgery
      • 4.3.2.2. Radiation Therapy
      • 4.3.2.3. Radiopharmaceuticals
      • 4.3.2.4. Chemotherapy
      • 4.3.2.5. Immunotherapy
      • 4.3.2.6. Gene Therapy
      • 4.3.2.7. Cryotherapy
      • 4.3.2.8. High-Intensity Focused Ultrasound
  • 4.4. By End-users
    • 4.4.1. Hospitals
    • 4.4.2. Ambulatory Surgical Centers
    • 4.4.3. Specialty Clinics
    • 4.4.4. Pharmacies
    • 4.4.5. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. South America
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Urinary Tract Cancer Market Outlook, By Region, 2017-2031F

  • 5.1 North America*
    • 5.1.1 Market Size & Forecast
      • 5.1.1.1 Value
      • 5.1.1.2 Volume
    • 5.1.2 By Types
      • 5.1.2.1 Kidney Cancer
      • 5.1.2.2 Bladder Cancer
      • 5.1.2.3 Ureteric and Renal Pelvic Cancer
      • 5.1.2.4 Urethral Cancer
    • 5.1.3 By Modality
      • 5.1.3.1 Diagnosis
      • 5.1.3.1.1 Urinalysis
      • 5.1.3.1.2 Cytology
      • 5.1.3.1.3 Cystoscopy
      • 5.1.3.1.4 MRI Scan
      • 5.1.3.1.5 CT Scan
      • 5.1.3.2 Treatment
      • 5.1.3.2.1 Surgery
      • 5.1.3.2.2 Radiation Therapy
      • 5.1.3.2.3 Radiopharmaceuticals
      • 5.1.3.2.4 Chemotherapy
      • 5.1.3.2.5 Immunotherapy
      • 5.1.3.2.6 Gene Therapy
      • 5.1.3.2.7 Cryotherapy
      • 5.1.3.2.8 High-Intensity Focused Ultrasound
    • 5.1.4 By End-users
      • 5.1.4.1 Hospitals
      • 5.1.4.2 Ambulatory Surgical Centers
      • 5.1.4.3 Specialty Clinics
      • 5.1.4.4 Pharmacies
      • 5.1.4.5 Others
    • 5.1.5 United States*
      • 5.1.5.1 Market Size & Forecast
      • 5.1.5.1.1 Value
      • 5.1.5.1.2 Volume
      • 5.1.5.2 By Types
      • 5.1.5.2.1 Kidney Cancer
      • 5.1.5.2.2 Bladder Cancer
      • 5.1.5.2.3 Ureteric and Renal Pelvic Cancer
      • 5.1.5.2.4 Urethral Cancer
      • 5.1.5.3 By Modality
      • 5.1.5.3.1 Diagnosis
      • 5.1.5.3.1.1 Urinalysis
      • 5.1.5.3.1.2 Cytology
      • 5.1.5.3.1.3 Cystoscopy
      • 5.1.5.3.1.4 MRI Scan
      • 5.1.5.3.1.5 CT Scan
      • 5.1.5.3.2 Treatment
      • 5.1.5.3.2.1 Surgery
      • 5.1.5.3.2.2 Radiation Therapy
      • 5.1.5.3.2.3 Radiopharmaceuticals
      • 5.1.5.3.2.4 Chemotherapy
      • 5.1.5.3.2.5 Immunotherapy
      • 5.1.5.3.2.6 Gene Therapy
      • 5.1.5.3.2.7 Cryotherapy
      • 5.1.5.3.2.8 High-Intensity Focused Ultrasound
      • 5.1.5.4 By End-users
      • 5.1.5.4.1 Hospitals
      • 5.1.5.4.2 Ambulatory Surgical Centers
      • 5.1.5.4.3 Specialty Clinics
      • 5.1.5.4.4 Pharmacies
      • 5.1.5.4.5 Others
    • 5.1.6 Canada
    • 5.1.7 Mexico

All segments will be provided for all regions and countries covered:

  • 5.2 Europe
    • 5.2.1 Germany
    • 5.2.2 France
    • 5.2.3 Italy
    • 5.2.4 United Kingdom
    • 5.2.5 Russia
    • 5.2.6 Netherlands
    • 5.2.7 Spain
    • 5.2.8 Turkey
    • 5.2.9 Poland
  • 5.3 South America
    • 5.3.1 Brazil
    • 5.3.2 Argentina
  • 5.4 Asia-Pacific
    • 5.4.1 India
    • 5.4.2 China
    • 5.4.3 Japan
    • 5.4.4 Australia
    • 5.4.5 Vietnam
    • 5.4.6 South Korea
    • 5.4.7 Indonesia
    • 5.4.8 Philippines
  • 5.5 Middle East & Africa
    • 5.5.1 Saudi Arabia
    • 5.5.2 UAE
    • 5.5.3 South Africa

6. Market Mapping, 2023

  • 6.1. By Types
  • 6.2. By Modality
  • 6.3. By End-users
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 10.1 Clinical Trials
  • 10.2 Patent Landscape
  • 10.3 Regulatory Approvals
  • 10.4 Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Bristol-Myers Squibb Company
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Novartis AG
  • 13.3. Merck & Co., Inc.
  • 13.4. Exelixis, Inc.
  • 13.5. AstraZeneca plc
  • 13.6. Astellas Pharma Inc.
  • 13.7. Johnson & Johnson Innovative Medicine
  • 13.8. Bayer AG
  • 13.9. Pfizer, Inc.
  • 13.10. Seagen Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 4. Global Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 5. Global Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 6. Global Urinary Tract Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 10. North America Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 11. North America Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 12. North America Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 16. United States Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 17. United States Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 18. Canada Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 21. Canada Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 22. Canada Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 23. Mexico Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 26. Mexico Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 27. Mexico Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 28. Europe Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 31. Europe Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 32. Europe Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 33. Europe Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 37. Germany Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 38. Germany Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 39. France Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 42. France Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 43. France Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 44. Italy Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 47. Italy Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 48. Italy Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 49. United Kingdom Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 52. United Kingdom Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 53. United Kingdom Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 54. Russia Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 57. Russia Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 58. Russia Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 59. Netherlands Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 62. Netherlands Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 63. Netherlands Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 64. Spain Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 67. Spain Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 68. Spain Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 69. Turkey Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 72. Turkey Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 73. Turkey Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 74. Poland Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 77. Poland Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 78. Poland Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 79. South America Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 82. South America Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 83. South America Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 84. South America Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 88. Brazil Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 89. Brazil Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 90. Argentina Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 93. Argentina Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 94. Argentina Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 95. Asia-Pacific Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 98. Asia-Pacific Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 99. Asia-Pacific Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 100. Asia-Pacific Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101. India Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 104. India Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 105. India Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 106. China Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 109. China Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 110. China Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 111. Japan Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 114. Japan Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 115. Japan Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 116. Australia Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 119. Australia Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 120. Australia Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 121. Vietnam Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 124. Vietnam Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 125. Vietnam Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 126. South Korea Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 129. South Korea Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 130. South Korea Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 131. Indonesia Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 134. Indonesia Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 135. Indonesia Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 136. Philippines Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 139. Philippines Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 140. Philippines Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 141. Middle East & Africa Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 144. Middle East & Africa Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 145. Middle East & Africa Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 146. Middle East & Africa Urinary Tract Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 150. Saudi Arabia Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 151. Saudi Arabia Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 152. UAE Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 155. UAE Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 156. UAE Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 157. South Africa Urinary Tract Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Urinary Tract Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Urinary Tract Cancer Market Share (%), By Types, 2017-2031F
  • Figure 160. South Africa Urinary Tract Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 161. South Africa Urinary Tract Cancer Market Share (%), By End-users, 2017-2031F
  • Figure 162. By Types Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023